혈관내피세포성장인자 억제제에 의한 구강편평상피세포암종 세포주의 성장 억제 효과

  • Han, Se-Jin (Dept. of OMFS. College of Dentistry, Dankook University) ;
  • Lee, Jae-Hoon (Dept. of OMFS. College of Dentistry, Dankook University)
  • 한세진 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 이재훈 (단국대학교 치과대학 구강악안면외과학교실)
  • Published : 2009.04.30


Tumor angiogenesis is a process leading to formation of blood vessels within tumors and is crucial for maintaining a supply of oxygen and nutrients to support tumor growth and metastasis. Vascular endothelial growth factor(VEGF) plays a key role in tumor angiogenesis including induction of endothelial cell proliferation, migration, survival and capillary tube formation. VEGF binds to two distinct receptors on endothelial cells. VEGFR-2 is considered to be the dominant signaling receptor for endothelial cell permeability, proliferation, and differentiation. Bevacizumab(Avastin, Genetech, USA) is a monoclonal antibody against vascular endothelial growth factor. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels. The goal of this study is to identify the anti-tumor effect of Bevacizumab(Avastin) for oral squamous cell carcinoma cell lines. Human squamous cell carcinoma cell line(HN4) was used in this study. We examined the sensitivity of HN4 cell line to Bevacizumab(Avastin) by using in vitro proliferation assays. The results were as follows. 1. In the result of MTT assay according to concentration of Bevacizumab(Avastin), antiproliferative effect for oral squamous cell carcinoma cell lines was observed. 2. The growth curve of cell line showed the gradual growth inhibition of oral squamous cell carcinoma cell lines after exposure of Bevacizumab(Avastin). 3. In the apoptotic index, groups inoculated Bevacizumab(Avastin) were higher than control groups. 4. In condition of serum starvation, VEGFR-2 did not show any detectable autophosphorylation, whereas the addition of VEGF activated the receptor. Suppression of phosphorylated VEGFR-2 and phosphorylated MAPK was observed following treatment with Bevacizumab(Avastin) in a dose-dependent manner. 5. In TEM view, dispersed nuclear membrane, scattered many cytoplasmic vacuoles and localized chromosomal margination after Bevacizumab(Avastin) treatment were observed. These findings suggest that Bevacizumab(Avastin) has the potential to inhibit MAPK pathway in proliferation of oral squamous cell carcinoma cell lines via inhibition of VEGF-dependent tumor growth.


  1. Kerbel RS : Tumor angiogenesis: past, present and the nearfuture. Carcinogenesis 21: 505-515, 2000
  2. Ferrara N, Henzel WJ : Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858, 1989
  3. Maglione D, Guerriero V, Viglietto G : Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271, 1991
  4. Maglione D, Guerriero V, Viglietto G : Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8:925-931, 1993
  5. Olofsson B, Pajusola K, Kaipainen A, : Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581, 1996
  6. Joukov V, Pajusola K, Kaipainen A : A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:1751-1758, 1996
  7. Lee J, Gray A, Yuan J, Luoh SM : Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988-1992, 1996
  8. Orlandini M, Marconcini L, Ferruzzi R : Identification of a c-fos-induced gene that is related to the plateletderived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 93:11675-11680, 1996
  9. Senger DR, Galli SJ, Dvorak AM : Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
  10. Dvorak HF, Brown LF, Detmar M: Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
  11. Benjamin LE, Golijanin D, Itin A : Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999
  12. Yancopoulos GD, Davis S, Gale NW : Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000
  13. Jain RK : Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003
  14. Ferrara N : Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl 1): 2-10, 2004
  15. Fontanini G, Vignati S, Boldrini L : Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3: 861-865, 1997
  16. Plouet J, Moukadiri HJ : Characterization of the receptors for vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem 265:22071-22075, 1990
  17. Vaisman N, Gospodarowicz D, Neufeld G : Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265:19461-19466, 1990
  18. Jakeman LB, Winer J, Bennett GL, Altar CA : Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253, 1992
  19. Jakeman LB, Armanini M, Philips HS : Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133:848-859, 1993
  20. Shen H, Clauss M, Ryan J : Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81:2767-2773, 1993
  21. Shibuya M, Yamaguchi S, Yamane A : Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8:519-527, 1990
  22. Matthews W, Jordan CT, Gavin M : A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88:9026-9030, 1991
  23. Terman BI, Carrion ME, Kovacs E : Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683, 1991
  24. Ruzinova MB, Schoer RA, Gerald W : Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4:277-289, 2003
  25. Ferrara N and Davis-Smyth T : The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997
  26. Presta LG, Chen H, O'Connor S1 : Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593- 4599, 1997
  27. Kim KJ, Li B, Houck K, Winer J : The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutra lizing monoclonal antibodies. Growth Factors 7: 53-64, 1992
  28. Gridelli C, Rossi A and Maione P : New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 60: 76-86, 2006
  29. Hurwitz H, Fehrenbacher L, Novotny W : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004
  30. Kabbinavar F, Hambleton I, Mass RD : Combined analysis of efficacy; the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005
  31. Iohnson DH, Fehrenbacher L, Novotny WF : Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Onco1 22: 2184-2191, 2004
  32. Cobleigh MA, Langmuir VK, Sledge GW : A phase I/Il dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124, 2003
  33. Borgstrom P, Bourdon MA and Ferrara N : Neutralizing anti-vascular endothelial growth factor, antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35: 1-10 1998<1::AID-PROS1>3.0.CO;2-O
  34. Berse B, Brown LF, and Senger DR : Vascular permeability factor(vasclar endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol BioI Cell 3: 211-220, 1992
  35. Folkman J, Merler E, Abernathy C : Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275-288, 1971
  36. Folkman J and Klagsbrun M : Angiogenic factors. Science 235:442-447, 1987
  37. Gospodarowicz D, Ferrara N, Schweigerer L : Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8:95-114, 1987
  38. Thomas KA, Rios-Candelore M, Gimenez-Gallego G : Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc Natl Acad Sci USA 82:6409-6413, 1985
  39. Esch F, Baird A, Ling N : Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82:6507-6511, 1985
  40. Jaye M, Howk R, Burgess W : Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization. Science 233:541-545, 1986
  41. Abraham JA, Mergia A, Whang JL : Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 233:545-548, 1986
  42. Gospodarowicz D and Thakral KK : Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc Natl Acad Sci USA 75:847-851, 1978
  43. Vlodavsky I, Folkman J, Sullivan R : Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296, 1987
  44. Matsuzaki K, Yoshitake Y, Matuo Y : Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci USA 86:9911- 9915, 1989
  45. Dennis PA and Rifkin DB : Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J Cell Physiol 144:84-98, 1990
  46. Houck KA, Ferrara N, Winer J : The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991
  47. Tischer E, Mitchell R, Hartman T : The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954, 1991
  48. Tournier C, Hess P, Yang DD : Requirement of JNK for stressinduced activation of the cytochrome c-mediated death pathway. Science. 288: 870-874, 2000
  49. Rajesh V, David S, Jeffery D : Expression of vascular endothelial growth factor receptors on tumor cells in head and neck aquamous cell carcinoma Arch Otolaryn Head Neck Surg 129; 882-888, 2003
  50. Volm M, Koomagi R, Mattern J : Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17:99-103, 1997
  51. Volm M, Koomagi R and Mattern J : Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74:64-68, 1997<64::AID-IJC11>3.0.CO;2-I
  52. Brown LF, Berse B, Jackman RW : Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
  53. Brown LF, Berse B, Jackman RW : Expression of vascular permeability factor(vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993
  54. Suzuki K, Hayashi N, Miyamoto Y : Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004-3009, 1996
  55. Uchida S, Shimada Y, Watanabe G : In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 77:1704-1709, 1998
  56. Brown LF, Berse B, Jackman RW : Increased expression of vascular permeability factor (vascular endothelial growth factor) and itsreceptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262, 1993
  57. Sowter HM, Corps AN, Evans AL : Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77:607-614, 1997
  58. Kim KJ, Li B, Winer J : Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993
  59. Presta LG, Chen H, O'Connor SJ : Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593- 4599, 1997
  60. Fong TA, Shawver LK, Sun L : SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999
  61. Wedge SR, Ogilvie DJ, Dukes M : ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60: 970-975, 2000
  62. D. Sano, M Kawakami, K Fujita : Antitumor effect of ZD6474 on head and neck squamous cell carcinoma. Oncology Reports 17; 289-295, 2007